Assessing blood-brain barrier dysfunction and its association with . . . Blood-brain barrier (BBB) alterations may contribute to AD pathology through various mechanisms, including impaired amyloid-β (Aβ) clearance and neuroinflammation Soluble platelet-derived growth factor receptor beta (sPDGFRβ) has emerged as a potential biomarker for BBB integrity
Blood brain barrier dysfunction in healthy aging and dementia: Why, how . . . During aging, the BBB becomes impaired, and it may contribute to the development of neurodegenerative and neurological disorders including Alzheimer’s disease and other dementias Restoring the BBB can be a strategy to prevent disease onset and development, reducing the symptoms of these conditions
Blood–Brain Barrier Breakdown in Relationship to Alzheimer and Vascular . . . Blood–brain barrier (BBB) breakdown has been suggested to be an early biomarker in human cognitive impairment However, the relationship between BBB breakdown and brain pathology, most commonly Alzheimer disease (AD) and vascular disease, is still poorly understood
Biomarker-based Alzheimer’s diagnosis: learning to use p-tau217 wisely The increasing complexity of personalised medicine to deliver targeted and highly specific therapeutics to patients for their disease depends on the diagnostic accuracy of our clinical medicine The very large multicohort study of participants with and without cognitive impairment presented by Ahn et al 1 illustrates the huge potential in the measurement of plasma p-tau217 supporting the